Keros Therapeutics (NASDAQ:KROS) Announces Quarterly Earnings Results

Keros Therapeutics (NASDAQ:KROS – Get Free Report) announced its quarterly earnings data on Monday. The company reported ($1.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.34) by $0.07, Briefing.com reports. During the same quarter last year, the firm earned ($1.13) earnings per share. Keros Therapeutics Price Performance NASDAQ:KROS traded down […]

Related Keywords

United States ,Hong Kong ,America ,Keith Regnante ,Piper Sandler ,Tower Research Capital ,Hong Kong Ltd ,Keros Therapeutics Company Profile ,Keros Therapeutics Inc ,Nasdaq ,Lazard Asset Management ,Almanack Investment Partners ,Keros Therapeutics ,Get Free Report ,Investment Partners ,Kong Ltd ,Research Capital ,Asset Management ,Amalgamated Bank ,Keros Therapeutics Daily ,Nasdaq Kros ,Zakros ,Medical ,Earnings ,